Medical Oncology

, Volume 29, Issue 5, pp 3314–3320 | Cite as

Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database

  • Alexandr Poprach
  • Zbyněk Bortlíček
  • Tomáš Büchler
  • Bohuslav Melichar
  • Radek Lakomý
  • Rostislav Vyzula
  • Petr Brabec
  • Marek Svoboda
  • Ladislav Dušek
  • Jakub Gregor
Original Paper


The incidence and mortality of renal cell carcinoma (RCC) in the Czech Republic are among the highest in the world. Several targeted agents have been recently approved for the treatment of advanced/metastatic RCC. Objective: Presentation of a national clinical database for monitoring and assessment of patients with advanced/metastatic RCC treated with targeted therapy. The RenIS (RENal Information System, registry is a non-interventional post-registration database of epidemiological and clinical data of patients with RCC treated with targeted therapies in the Czech Republic. Twenty cancer centres eligible for targeted therapy administration participate in the project. As of November 2011, six agents were approved and reimbursed from public health insurance, including bevacizumab, everolimus, pazopanib, sorafenib, sunitinib, and temsirolimus. As of 10 October 2011, 1,541 patients with valid records were entered into the database. Comparison with population-based data from the Czech National Cancer Registry revealed that RCC patients treated with targeted therapy are significantly younger (median age at diagnosis 59 vs. 66 years). Most RenIS registry patients were treated with sorafenib and sunitinib, many patients sequentially with both agents. Over 10 % of patients were also treated with everolimus in the second or third line. Progression-free survival times achieved were comparable to phase III clinical trials. The RenIS registry has become an important tool and source of information for the management of cancer care and clinical practice, providing comprehensive data on monitoring and assessment of RCC targeted therapy on a national level.


Renal cell carcinoma Targeted therapy Clinical registry Cancer care Database Population-based data 



Authors would like to thank all cancer centres involved in data collection for the RenIS registry: University Hospital Brno—Otakar Bednařík, MD; St. Ann’s University Hospital, Brno—Jana Katolická, MD, PhD; Masaryk Memorial Cancer Institute, Brno—prof. Rostislav Vyzula, MD, PhD; Hospital České Budějovice—Václav Janovský, MD, Alena Šináklová, MD; University Hospital Hradec Králové—prof. Jiří Petera, MD, PhD, Josef Dvořák, MD, PhD; Hospital Chomutov—Martina Chodacká, MD; Hospital Jihlava—Lubomír Slavíček, MD, Věra Benešová, MD; Regional Hospital Liberec—Jiří Bartoš, MD, MBA, Věra Hejzlarová, MD; Hospital and Health Centre in Nový Jičín—assoc. prof. Renata Soumarová, MD, PhD, MBA, Josef Gruna, MD; University Hospital Olomouc—prof. Bohuslav Melichar, MD, PhD, Petr Beneš, MD, PhD; University Hospital Ostrava—David Feltl, MD, PhD, Martina Vybíralová, MD; Regional Hospital Pardubice—assoc. prof. Jaroslav Vaňásek, MD, PhD, Iveta Kolářová, MD; University Hospital Plzeň—assoc. prof. Jindřich Fínek, MD, PhD, Vladimíra Arnetová, MD; Hospital Na Bulovce, Prague—Vladimíra Stáhalová, MD; Hospital Na Homolce, Prague—Martin Šafanda, MD, PhD; General University Hospital in Prague—prof. Luboš Petruželka, MD, PhD; University Hospital Motol, Prague—Jana Prausová, MD, PhD, Stanislav Batko, MD; Thomayer Hospital, Prague—prof. Jitka Abrahámová, MD, PhD; Masaryk Hospital in Usti nad Labem—Milan Lysý, MD, David Šulc, MD; T. Baťa Regional Hospital, Zlín—Milan Kohoutek, MD, Alena Jakšičová, MD. This work was supported by the Project MZ0MOU2005 of the Czech Ministry of Health. The RenIS registry is supported by research grants from Novartis, Pfizer, Bayer, Roche, and GlaxoSmithKline.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC CancerBase no. 10 (online). International Agency for Research on Cancer, Lyon, France, 2010. Available from:
  2. 2.
    Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. Epidemiology of malignant tumours in the Czech Republic (online). Masaryk University, Czech Republic. 2005. Available from: Version 7.0 [2007], ISSN 1802-8861.
  3. 3.
    Dušek L, Mužík J, Gelnarová E, Fínek J, Vyzula R, Abrahámová J. Cancer incidence and mortality in the Czech Republic (in Czech). Klin Onkol. 2010;23(5):311-24.Google Scholar
  4. 4.
    Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011;108(10):1556–63.PubMedCrossRefGoogle Scholar
  5. 5.
    Jäger D, Ma J, Korbenfeld E, Zemanová M, Leonhartsberger N, Stauch K, et al. PREDICT (Patient Characteristics in REnal Cell Carcinoma and Daily PractICe Treatment With Sorafenib) non-interventional study—final report. Eur J Cancer. 2011;47(1):S520.CrossRefGoogle Scholar
  6. 6.
    Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab refractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26(22):3743–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol. 2010;58(6):906–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, et al. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer. 2010;116(23):5383–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer. 2011;105(11):1635–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Grünwald V, Weikert S, Seidel C, Busch J, Johannsen A, Fenner M, et al. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie. 2011;34(6):310–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Bergmann L, Kube U, Kindler M, Koepke T, Steiner G, Janssen J, et al. A noninterventional study of everolimus in metastatic renal cell cancer after use of one VEGFR-TKI: results of a preplanned interim analysis of a prospective study. American Society of Clinical Oncology (ASCO) annual meeting; 3–7 June 2011; Chicago, Illinois, USA.Google Scholar
  12. 12.
    Büchler T, Klapka R, Melichar B, Brabec P, Dušek L, Vyzula R, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma—data from the Czech registry. Ann Oncol. 2012;23(2):395–401.PubMedCrossRefGoogle Scholar
  13. 13.
    Nadkarni PM, Brandt C, Frawley S, Sayward FG, Einbinder R, Zelterman D, et al. Managing attribute—value clinical trials data using the ACT/DB client–server database system. J Am Med Inf Assoc. 1998;5(2):139–51.CrossRefGoogle Scholar
  14. 14.
    Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. AVOREN trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma final results and analysis of prognostic factors. Cancer. 2010;116(18):4256–65.PubMedCrossRefGoogle Scholar
  16. 16.
    Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.PubMedCrossRefGoogle Scholar
  17. 17.
    Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.PubMedCrossRefGoogle Scholar
  18. 18.
    Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.PubMedCrossRefGoogle Scholar
  19. 19.
    Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004.Google Scholar
  20. 20.
    Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, Zama I, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology. 2010;76(2):430–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ, Tan MH, et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol. Nov 5 2011 [Epub ahead of print].Google Scholar
  22. 22.
    Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol. 2011;60(6):1163–70.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Alexandr Poprach
    • 1
  • Zbyněk Bortlíček
    • 2
  • Tomáš Büchler
    • 3
  • Bohuslav Melichar
    • 4
  • Radek Lakomý
    • 1
  • Rostislav Vyzula
    • 1
  • Petr Brabec
    • 2
  • Marek Svoboda
    • 1
  • Ladislav Dušek
    • 2
  • Jakub Gregor
    • 2
  1. 1.Department of Complex Oncology CareMasaryk Memorial Cancer InstituteBrnoCzech Republic
  2. 2.Institute of Biostatistics and AnalysesMasaryk UniversityBrnoCzech Republic
  3. 3.Department of Oncology, First Faculty of MedicineThomayer Hospital and Charles UniversityPragueCzech Republic
  4. 4.Department of OncologyPalacký University Medical School and Teaching Hospital OlomoucOlomoucCzech Republic

Personalised recommendations